Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8

Benzinga · 1d ago
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and raises the price target from $4 to $8.